507 related articles for article (PubMed ID: 21396117)
1. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Burga LN; Hu H; Juvekar A; Tung NM; Troyan SL; Hofstatter EW; Wulf GM
Breast Cancer Res; 2011 Mar; 13(2):R30. PubMed ID: 21396117
[TBL] [Abstract][Full Text] [Related]
2. Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers.
Burga LN; Tung NM; Troyan SL; Bostina M; Konstantinopoulos PA; Fountzilas H; Spentzos D; Miron A; Yassin YA; Lee BT; Wulf GM
Cancer Res; 2009 Feb; 69(4):1273-8. PubMed ID: 19190334
[TBL] [Abstract][Full Text] [Related]
3. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
Strecker TE; Shen Q; Zhang Y; Hill JL; Li Y; Wang C; Kim HT; Gilmer TM; Sexton KR; Hilsenbeck SG; Osborne CK; Brown PH
J Natl Cancer Inst; 2009 Jan; 101(2):107-13. PubMed ID: 19141783
[TBL] [Abstract][Full Text] [Related]
4. Tip30 deletion in MMTV-Neu mice leads to enhanced EGFR signaling and development of estrogen receptor-positive and progesterone receptor-negative mammary tumors.
Zhang C; Mori M; Gao S; Li A; Hoshino I; Aupperlee MD; Haslam SZ; Xiao H
Cancer Res; 2010 Dec; 70(24):10224-33. PubMed ID: 21159643
[TBL] [Abstract][Full Text] [Related]
5. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
Regan JL; Kendrick H; Magnay FA; Vafaizadeh V; Groner B; Smalley MJ
Oncogene; 2012 Feb; 31(7):869-83. PubMed ID: 21765473
[TBL] [Abstract][Full Text] [Related]
6. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.
Ma Z; Parris AB; Xiao Z; Howard EW; Kosanke SD; Feng X; Yang X
J Exp Clin Cancer Res; 2017 Jan; 36(1):6. PubMed ID: 28061785
[TBL] [Abstract][Full Text] [Related]
7. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
8. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
[TBL] [Abstract][Full Text] [Related]
9. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
[TBL] [Abstract][Full Text] [Related]
11. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
12. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
[TBL] [Abstract][Full Text] [Related]
13. Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.
Bade LK; Goldberg JE; Dehut HA; Hall MK; Schwertfeger KL
J Cell Sci; 2011 Sep; 124(Pt 18):3106-17. PubMed ID: 21868365
[TBL] [Abstract][Full Text] [Related]
14. Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers.
Zvelebil M; Oliemuller E; Gao Q; Wansbury O; Mackay A; Kendrick H; Smalley MJ; Reis-Filho JS; Howard BA
Breast Cancer Res; 2013 Mar; 15(2):R25. PubMed ID: 23506684
[TBL] [Abstract][Full Text] [Related]
15. New insights into lineage restriction of mammary gland epithelium using parity-identified mammary epithelial cells.
Chang TH; Kunasegaran K; Tarulli GA; De Silva D; Voorhoeve PM; Pietersen AM
Breast Cancer Res; 2014 Jan; 16(1):R1. PubMed ID: 24398145
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 regulates human mammary stem/progenitor cell fate.
Liu S; Ginestier C; Charafe-Jauffret E; Foco H; Kleer CG; Merajver SD; Dontu G; Wicha MS
Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1680-5. PubMed ID: 18230721
[TBL] [Abstract][Full Text] [Related]
17. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells.
Ma Y; Katiyar P; Jones LP; Fan S; Zhang Y; Furth PA; Rosen EM
Mol Endocrinol; 2006 Jan; 20(1):14-34. PubMed ID: 16109739
[TBL] [Abstract][Full Text] [Related]
18. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
[TBL] [Abstract][Full Text] [Related]
19. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
Sinha A; Paul BT; Sullivan LM; Sims H; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
Oncotarget; 2017 Feb; 8(6):10114-10135. PubMed ID: 28052035
[TBL] [Abstract][Full Text] [Related]
20. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
